Background
MDM2 gene
The biology function of MDM2
The relationship between MDM2 and p53
The relationship between MDM2 and other proteins
Role of MDM2 and therapeutic resistance
MDM2 overexpression and chemotherapeutic resistance
MDM2–p53 loop-dependent drug resistance
MDM2–p53 loop-independent drug resistance
Relationship between MDM2 overexpression and radiotherapy
MDM2 overexpression and TKIs resistance
Signaling pathway bypass activation
Inhibition of tumor cell apoptosis
Promotion of epithelial mesenchymal transformation
Promotion of sustained angiogenesis
MDM2 overexpression and hyperprogressive disease of immunotherapy
Alteration induced by MDM2 amplification and overexpression | Downstream factors | Related therapeutic resistance | References |
---|---|---|---|
Inhibition of cisplatin-induced apoptosis | – | Cisplatin | [18] |
MDM2–p53 loop | P53↓ | Cisplatin, doxorubicin, gemcitabine, 5-FU, radiotherapy | |
MDM2–p53 loop | P53↓, MGMT↑ | Temozolomide | [20] |
EMT | Invasion and migration | Chemotherapy, target therapy | |
MDM2–p53 loop | NF-κB signaling pathway↑ | TKIs | |
MDM2–p53 loop | P53↓, Bax↓, Bcl-2↑ | TKIs | |
MDM2–p53 loop | VEGF↑, PDGF↑ | TKIs | |
NFATc2↓ | T cell activation↓ | Immunotherapy | [47] |
Serves as a TAA | Immunological tolerance | Immunotherapy |